Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more
Solara Active Pharma Sciences Limited (SOLARA) - Net Assets
Latest net assets as of September 2025: ₹12.57 Billion INR
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has net assets worth ₹12.57 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹22.93 Billion) and total liabilities (₹10.36 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹12.57 Billion |
| % of Total Assets | 54.83% |
| Annual Growth Rate | 348.5% |
| 5-Year Change | -31.13% |
| 10-Year Change | N/A |
| Growth Volatility | 3793152.16 |
Solara Active Pharma Sciences Limited - Net Assets Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual net assets of Solara Active Pharma Sciences Limited from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹10.97 Billion | +17.12% |
| 2024-03-31 | ₹9.37 Billion | -37.66% |
| 2023-03-31 | ₹15.02 Billion | -2.10% |
| 2022-03-31 | ₹15.35 Billion | -3.64% |
| 2021-03-31 | ₹15.93 Billion | +46.09% |
| 2020-03-31 | ₹10.90 Billion | +13.54% |
| 2019-03-31 | ₹9.60 Billion | +24.96% |
| 2018-03-31 | ₹7.68 Billion | +11469422.39% |
| 2017-03-31 | ₹67.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solara Active Pharma Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 315626700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹402.50 Million | 3.68% |
| Other Comprehensive Income | ₹9.60 Million | 0.09% |
| Other Components | ₹13.69 Billion | 125.08% |
| Total Equity | ₹10.94 Billion | 100.00% |
Solara Active Pharma Sciences Limited Competitors by Market Cap
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SHANDONG BOAN BIOTECH.H 1
F:UJ9
|
$145.58 Million |
|
PNGJL
NSE:PNGJL
|
$145.62 Million |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
$145.66 Million |
|
British American Tobacco Malaysia Bhd
KLSE:4162
|
$145.66 Million |
|
Gigasolar Materials
TWO:3691
|
$145.51 Million |
|
Nordrest Holding AB (publ)
ST:NREST
|
$145.50 Million |
|
Pendrell Corp
PINK:PCOA
|
$145.50 Million |
|
Shanghai Conglin Environmental Protection Technology Co. Ltd. A
SHG:688370
|
$145.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solara Active Pharma Sciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,339,100,000 to 10,942,400,000, a change of 1,603,300,000 (17.2%).
- Net income of 5,400,000 contributed positively to equity growth.
- Share repurchases of 1,590,200,000 reduced equity.
- New share issuances of 1,590,200,000 increased equity.
- Other comprehensive income increased equity by 15,599,999.
- Other factors increased equity by 1,582,300,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹5.40 Million | +0.05% |
| Share Repurchases | ₹1.59 Billion | -14.53% |
| Share Issuances | ₹1.59 Billion | +14.53% |
| Other Comprehensive Income | ₹15.60 Million | +0.14% |
| Other Changes | ₹1.58 Billion | +14.46% |
| Total Change | ₹- | 17.17% |
Book Value vs Market Value Analysis
This analysis compares Solara Active Pharma Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 71772.57x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | ₹0.01 | ₹429.40 | x |
| 2018-03-31 | ₹295.21 | ₹429.40 | x |
| 2019-03-31 | ₹386.56 | ₹429.40 | x |
| 2020-03-31 | ₹405.71 | ₹429.40 | x |
| 2021-03-31 | ₹462.97 | ₹429.40 | x |
| 2022-03-31 | ₹424.27 | ₹429.40 | x |
| 2023-03-31 | ₹416.77 | ₹429.40 | x |
| 2024-03-31 | ₹239.11 | ₹429.40 | x |
| 2025-03-31 | ₹283.70 | ₹429.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solara Active Pharma Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.04%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 2.04x
- Recent ROE (0.05%) is below the historical average (50019.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 450208.96% | 3.20% | 94127.80x | 1.49x | ₹301.63 Million |
| 2018 | 0.05% | 0.07% | 0.29x | 2.38x | ₹-760.21 Million |
| 2019 | 6.23% | 4.50% | 0.67x | 2.05x | ₹-360.60 Million |
| 2020 | 10.55% | 9.04% | 0.59x | 1.98x | ₹60.16 Million |
| 2021 | 13.94% | 13.87% | 0.61x | 1.65x | ₹625.48 Million |
| 2022 | -3.81% | -4.58% | 0.43x | 1.94x | ₹-2.11 Billion |
| 2023 | -1.48% | -1.55% | 0.49x | 1.93x | ₹-1.72 Billion |
| 2024 | -60.75% | -44.02% | 0.55x | 2.52x | ₹-6.61 Billion |
| 2025 | 0.05% | 0.04% | 0.58x | 2.04x | ₹-1.09 Billion |
Industry Comparison
This section compares Solara Active Pharma Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solara Active Pharma Sciences Limited (SOLARA) | ₹12.57 Billion | 450208.96% | 0.82x | $145.55 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |